The Prosigna test is an advanced molecular examination used to assess the risk of breast cancer recurrence in women with early-stage disease. It is based on analyzing gene expression in the tumor and provides essential information to guide treatment decisions.
The Prosigna test is primarily used to help assess the risk of breast cancer recurrence and is indicated in specific situations. It is based on the tumor’s molecular profile and helps guide treatment decisions.
Sestak I, Buus R, Cuzick J, et al. JAMA Oncol. 2018; 4(4):545-553
The clinically validated algorithm generates a unique score for each patient.
Consider this test in the following cases:
Note: Prosigna is not indicated for patients with HER2+ tumors or those with estrogen receptor-negative (ER-) tumors, as the test was specifically developed for ER+/HER2- tumors.
The panel includes:
The methodology used for this test is as follows:
Biopsy: In paraffin block or slide
Up to 30 calendar days.
Medical request.
| Type | Description |
| Technique | Microarray |
| Accuracy | 80-85% |
Main Office Rua Bento Gonçalves, 59, Room 802 — Centro, Marau, RS — 99150-000
Porto Alegre Office Rua Gomes Jardim, 301 , Room 918/909 — Santana, Porto Alegre, RS — 90620-130